Master data| INID | Criterion | Field | Content |
|---|
| Type of IP right | SART | Patent |
| Status | ST | Pending/in force |
| 21 | DE file number | DAKZ | 60 2006 059 843.2 |
| 96 | EP file number | EAKZ | 17 19 2971.4 |
| 97 | EP publication number | EPN | 3321359 |
| 54 | Designation/title | TI | VARIANTE FORMEN VON URATOXIDASE UND VERWENDUNG DAVON |
| 51 | IPC main class | ICM (ICMV) | C12N 9/06 (2006.01) |
| 51 | IPC secondary class(es) | ICS (ICSV) | A61K 47/60 (2017.01) |
| 22 | DE application date | DAT | Apr 11, 2006 |
| 96 | EP application date | EAT | Apr 11, 2006 |
| 43 | Date of first publication | OT | May 16, 2018 |
| Date of publication of grant | PET | Dec 2, 2020 |
| 71/73 | Applicant/owner | INH | Horizon Therapeutics USA, Inc., Deerfield, IL, US |
| 72 | Inventor | IN | HARTMAN, Jacob, 58453 Holon, IL; MENDELOVITZ, Simona, 69341 Ramat Aviv, IL |
| 74 | Representative | VTR | Müller-Boré & Partner Patentanwälte PartG mbB, 80639 München, DE |
| Address for service | | Müller-Boré & Partner Patentanwälte PartG mbB, 80639 München, DE |
33 31 32
| Foreign priority | PRC PRNA PRDA
| US 670573 P Apr 11, 2005
|
| Patent division in charge | | 44 |
| 97 | EP language of publication | ELANG | EN - Englisch |
| 84 | Designated EP contracting states | EDS | AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR |
| Published EP/WO documents | EPWOPN | Original document:
EP000003321359A1 Searchable text:
EP000003321359A1 Original document:
EP000003321359B1 Searchable text:
EP000003321359B1 |
| 43 | Date of first publication | EVT | May 16, 2018 |
| Date of the first transfer into DPMAregister | EREGT | May 16, 2018 |
| Date of the (most recent) update in DPMAregister | REGT | Nov 21, 2025 (Show all update days)(Hide all update days)- Nov 21, 2025
- Procedures: Procedure relating to EP application, EPO publication of mention of grant , 02.12.2020: new
- Procedures: Procedure relating to EP application, EPO publication of mention of grant , 02.12.2020: deleted
- Mar 28, 2025
- May 9, 2024; Apr 20, 2024; Aug 31, 2023; Aug 1, 2023; Apr 20, 2023; Apr 21, 2022; Nov 25, 2021; Oct 21, 2021; May 4, 2021; Mar 2, 2021; Dec 17, 2020; Nov 12, 2020
- Historical data not available for this/these date(s)
- May 16, 2018
- Date of the first transfer into DPMAregister
|
View procedures New applicant/owner details (No.: 6)| INID | Criterion | Field | Content
Close details
|
|---|
| Type of procedure | VART | New applicant/owner details |
| Legal/procedural status | VST | New applicant/owner details |
| Date of legal/procedural status | VSTT | Jul 31, 2023 |
| Issue number | HN | 36 |
| Year | PJ | 2023 |
| Publication date | VT | Sep 7, 2023 |
| Type of publication | PART | Bibliographic data |
| Part | HT | Part 3 |
| 71/73 | Applicant/owner | INH | Horizon Therapeutics USA, Inc., Deerfield, IL, US |
| 71/73 | Previous applicant/owner | INHF | Horizon Pharma Rheumatology LLC, Lake Forest, IL, US |
| Date of update of the procedure | REGT | Aug 31, 2023 |